BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    

Alltracel Pharmaceuticals Plc Appoints Manufacturing And Business Development Partner, Neoplast Company Ltd., For Its m-doc(TM) Technology Platform In The $1.2 Billion Asia Pacific Woundcare Market

10/19/2005 5:10:00 PM

BANGKOK, Thailand and DUBLIN, Ireland, Feb. 12 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., the AIM listed (AIM: AP.L), biopharmaceutical R&D company specializing in medical devices and compounds, and owners of the stops-bleeding m-doc(TM) first-aid ingredient brand and SEAL-ON(TM) the first- aid treatment brand featuring stops-bleeding as standard, is pleased to announce the signing of a letter-of-intent with the Neoplast Company Ltd. towards their formal appointment as Alltracel's Manufacturing and Business Development partner for the retail, professional and industrial sectors in the $1.2billion Asia Pacific woundcare market.

Bangkok based Neoplast will become Alltracel's regional partner for the conversion of its m-doc(TM) technology platform into various innovative wound treatment products effective March 01. Alltracel revenue flows are expected to commence next quarter.

Neoplast Company Ltd, ( is a leading manufacturer/distributor of surgical tapes and dressings and first aid bandages for both the professional and consumer markets across the Asia Pacific region. They have their own highly innovative product development division which will ensure m-doc(TM) based products can be suitably adapted for this market. Neoplast's exports account for 70% of their business and among their clients are world-leading companies in the field of wound-care. Mr. Sawat Donsagul, Chairman and Managing Director of Neoplast commented:

"Since our establishment in 1988 we have grown our business on our reputation as an innovative company using the latest production technologies. The addition of the m-doc(TM) technology platform is totally in keeping with this approach. We are very excited about working with the Alltracel team and developing the m-doc(TM) technology and product range and spearheading the extension of the m-doc(TM) co-brand partnership program across the Asia Pacific region."

Speaking on this regional market breakthrough Donal O'Brien Alltracel's Chief Operating Officer (COO) commented:

"This agreement in Asia now extends our manufacturing/conversion partners to the three main continents. This is crucial to allow us to develop and market products using our m-doc(TM) technology platform that are specific to each region. As well as launching m-doc(TM) in their own Neo-Pro first-aid brand range, Neoplast will be driving the m-doc(TM) co-brand partnership program recruiting private label and third party proprietary brands in this territory. We look forward to working with Neoplast in making stops-bleeding a standard across the first-aid market."

Notes to Editors follow:

Alltracel ( ) -- Alltracel Pharmaceuticals PLC is an innovative bio-pharmaceutical company specializing in medical devices and compounds, which control bleeding and accelerate the natural healing process efficiently. Headquartered in Dublin, Ireland and with an R&D subsidiary in the Czech Republic, Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.

m-doc(TM) (Micro Dispersed Oxidized Cellulose) ( ) is the end product of Alltracel's patented process, applied to cotton in the form of raw cellulose and is proven as an effective and efficient haemostatic (blood- stopping) agent in wound care devices. The route-to-market is via licensed trademark and ingredient supply agreements with existing recognized wound care brands.

SEAL-ON(TM) ( ) is the world's first first-aid treatment brand featuring stops bleeding m-doc(TM) as standard. The SEAL-ON(TM) range features six different product delivery systems -- including sprays, nasal plugs, patches and plasters -- each designed for specific usage occasions and all containing the stops-bleeding m-doc(TM) ingredient brand.

R&D on the core -- polysaccharides manipulation -- technology platform has confirmed significant and exciting potential applications beyond the Wound-care market, primarily in the Dermatological and Nutritional Foods market sectors.

Alltracel Pharmaceuticals PLC

CONTACT: Dublin, Denise Cronin, Alltracel, +353-1-235-2162,; London, Debbie Ardern-Jones, +44-0207-269-7110, New York,Tiernan Cavanna, Financial Dynamics, +1-212-850-5600, both of FinancialDynamics for Alltracel

Read at